Cassava Starts Second Alzheimer's Study After PT-125 Effects Multiple Biomarkers

The company formerly known as Pain Therapeutics revealed a 100% response rate in a small Phase IIa study and hopes to confirm the novel drug's effects on all biomarkers tested in Phase IIb.

Neurons and nervous system. 3d render of nerve cells
PTI-125 may help restore normal function of neurons. • Source: Shutterstock

Cassava Sciences Inc. delivered its first set of data from a small study in Alzheimer's disease for PTI-125, its only remaining clinical-stage drug since the company changed its name from Pain Therapeutics Inc. in March. The small molecule, which has a novel mechanism of action in a disease that needs fresh treatment approaches, generated a 100% response rate in the 13-patient Phase II clinical trial and impacted all nine biomarkers assessed in the study.

Pain Therapeutics changed its name to Cassava as its focus shifted from the abuse-deterrent opioid Remoxy, which was rejected by...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Pfizer’s Hympavzi Poised For Broader Hemophilia Label

 

The drugmaker announced positive topline results for the drug in hemophilia A and B patients with inhibitors, on top of the existing approval for patients without inhibitors.

Vor Is Reborn With New CEO And Ambitious RemeGen Autoimmune Pact

 
• By 

The biotech had been looking at options to survive since May.

Biogen’s Spinraza Follow-On May Offer Disease-Modifying Potential

 
• By 

Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.

Nuvalent Believes Safety Profile Can Help Zidesamtinib Be ROS-1 Lung Cancer Leader

 

Zidesamtinib would be the fifth ROS-1 targeting therapy on the market, but Nuvalent believes its safety and efficacy profile will make it the best in class.

More from R&D

Nuvalent Believes Safety Profile Can Help Zidesamtinib Be ROS-1 Lung Cancer Leader

 

Zidesamtinib would be the fifth ROS-1 targeting therapy on the market, but Nuvalent believes its safety and efficacy profile will make it the best in class.

Nektar Bounces Back As Eczema Drug Rezpeg Heads For Phase III

 
• By 

Lilly-rejected candidate impresses in Phase IIb atopic dermatitis trial.

Amgen’s MariTide Data Not The Hit Investors Sought

 
• By 

MariTide demonstrated solid 52-week weight loss in a Phase II update, but high rates of vomiting. Amgen is adjusting dosing in Phase III to seek a better tolerability profile.